Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

AIM WINNERS & LOSERS: Genedrive hails positive test kit trial results

27th Dec 2024 10:25

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Friday.

----------

AIM - WINNERS

----------

Nostra Terra Oil & Gas Co PLC, up 18% at 0.025p, 12-month range 0.021p-0.1725p. City broker Peel Hunt LLP has a 10.08% stake in the Texas, US-focused oil producer as of Monday, up from none reported previously.

----------

Genedrive PLC, up 4.4% at 2.375 pence, 12-month range 1.45p-8.125p. The Manchester-based point-of-care pharmacogenetic testing company announces the publication of positive test results for its CYP2C19-ID point-of-care genetic testing kit. The kit is recommended by the UK National Institute for Health & Care Excellence for use by the NHS for prescribing clopidogrel in ischaemic stroke and transient ischaemic attack, using a cheek swab sample to "rapidly" identify "several important [loss of function] genetic variants of the CYP2C19 gene". These include variants which are not included in other platforms' targets, and which are "more prevalent in specific ethnic groups". Genedrive says that in the 202-strong patient cohort, the CYP2C19-ID kit was "substantially less expensive" than laboratory testing and "outperformed" it in speed, accuracy in identification, and in the rate of test failures. It showed 100% sensitivity and specificity with a failure rate of 0.98%, three times lower than laboratory testing, and identified seven patients with LOF variants that conventional tests would not have detected. Genedrive says the study confirms "that the Genedrive System is able to provide an accurate, rapid, non-invasive alternative to standard laboratory testing and can be used as a point of care test in the clinical environment".

----------

AIM - LOSERS

----------

EPE Special Opportunities, down 0.3% at 151.5p, 12-month range 147.5p-187p. The investment firm, which backs small and medium-sized companies, announces that it no longer intends to undertake share buybacks. Says it has repurchased 175,000 shares since December 6, when it announced its intention to conduct the buybacks although it warned at the time: "The board believes that the current low level of liquidity in its issued ordinary shares may limit the progress in buying back shares." Does not on Friday rule out the possibility of buybacks in the future, but at present only says it will announce any future repurchasing plans "as applicable, in due course".

----------

By Emma Curzon, Alliance News reporter

Comments and questions to [email protected]

Copyright 2024 Alliance News Ltd. All Rights Reserved.

FTSE 100 Latest
Value8,149.78
Change12.79